...
首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >Durable Suppression of Disease Activity by Alemtuzumab in the Absence of Continuous Treatment Over 6 Years in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy (CARE-MS II)
【24h】

Durable Suppression of Disease Activity by Alemtuzumab in the Absence of Continuous Treatment Over 6 Years in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy (CARE-MS II)

机译:Alemtuzumab持续抑制Alemtuzumab在患有6岁以下患者的患者中缺乏持续治疗的患者,患者有活性复发 - 延髓多发性硬化和对先前治疗的反应不足(Care-MS II)

获取原文
获取原文并翻译 | 示例
           

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号